Evidence map›Paper›PMID 38964031›Full record

ArticleTranslational oncology2024

Comprehensive investigation in oncogenic functions and immunological roles of NCBP2 and its validation in prostate cancer.

Jian Wang, Tao Guo, Xiaomin Zhang, Jiacheng Guo, Xiangyu Meng, Shi Yan, Ye Wang, Yutian Xiao, Weidong Xu, Xuedong Wei and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Bolstering CD8Biology · 2025
    Review
  3. Journal of inflammation research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jian WangDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China; Department of Urology, Shanghai Changzheng Hospital, Shanghai, China; Department of Urology, Shanghai Changhai Hospital, Shanghai, China; Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, China.
Tao GuoDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiaomin ZhangDepartment of Urology, Shanghai Changhai Hospital, Shanghai, China.
Jiacheng GuoCAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
Xiangyu MengDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing China.
Shi YanDepartment of Urology, Shanghai Changhai Hospital, Shanghai, China.
Ye WangDepartment of Urology, Shanghai Changzheng Hospital, Shanghai, China.
Yutian XiaoDepartment of Urology, Shanghai Changhai Hospital, Shanghai, China.
Weidong XuDepartment of Urology, Shanghai Changzheng Hospital, Shanghai, China.
Xuedong WeiDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Keke DingDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jun ZhangDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yuanyuan MiDepartment of Urology, Affiliated Hospital of Jiangnan University, Wuxi, China.
Sheng WuDepartment of Urology, Affiliated Hospital of Jiangnan University, Wuxi, China.
Jie ChenDepartment of Urology, Shanghai Changzheng Hospital, Shanghai, China. Electronic address: rexcj8298@163.com.
Yuhua HuangDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China. Electronic address: sdfyy_hyh@163.com.
Shancheng RenDepartment of Urology, Shanghai Changzheng Hospital, Shanghai, China. Electronic address: renshancheng@gmail.com.
Jianquan HouDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China. Electronic address: xf192hou@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNuclear cap-binding protein 2 (NCBP2), as the component of the cap-binding complex, participates in a number of biological processes, including pre-mRNA splicing, transcript export, translation regulation and other gene expression steps. However, the role of NCBP2 on the tumor cells and immune microenvironment remains unclear. To systematically analyze and validate functions of NCBP2, we performed a pan-cancer analysis using multiple approaches.

methodsThe data in this study were derived from sequencing, mutation, and methylation data in the TCGA cohort, normal sample sequencing data in the GTEx project, and cell line expression profile data in the CCLE database.

resultsSurvival analyses including the Cox proportional-hazards model and log-rank test revealed the poor prognostic role of NCBP2 in multiple tumors. We further validated the oncogenic ability of NCBP2 in prostate cancer cell lines, organoids and tumor-bearing mice. A negative correlation was observed between NCBP2 expression and immune score by the ESTIMATE algorithm. Simultaneously, the NCBP2-induced immunosuppressive microenvironment might be related to the decline in CD8

conclusionThis research offered strong proof supporting NCBP2 as the prognostic marker and the therapeutic target in the future.

Indexed as

NCBP2Pan-cancerPrognosisProstate cancerTherapeutic targetTumor microenvironment

Identifiers

PMID38964031
PMCPMC11283080

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.